Carnitine for the Treatment of Atherosclerosis.
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 177 participants.
Also called NCT02117661
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 177 participants
- Registry
-
NCT02117661
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT02117661. Randomized; double masking; primary purpose treatment. Start 2015-01 (actual); primary completion 2017-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Carnitine for the Treatment of Atherosclerosis.
- Acronym
- ECoM
- Condition
- Metabolic Syndrome
- Intervention (Dietary supplement)
- L-carnitine capsules
- Intervention (Dietary supplement)
- Cellulose capsules
- Lead sponsor
- Dr. Amer Johri
- Collaborator
- Heart and Stroke Foundation of Canada
- Collaborator
- Queen's University
Record details
- Record id
cardio:ct-nct02117661- Content hash
75fa21d432f3e23a8cf1506ffbbb8acb22e2b4c74cf289d00185c151e00b77bb